News
Malaysia To Showcase Bio-Xcell, Biotech Advantages At Bio Chicago
30 April 2010
The 70-member delegation, with extensive biotechnology background, will "rub shoulders" with Who's Who in the biotechnology industry to convince them on the ...
Click on the link to read the full article at Bernama (This link will open in a new window)Business Forum to Address Biotechnology in US
30 April 2010
May 5, 2010 at DePaul Center in downtown Chicago will focus on the entrepreneurial and innovative importance and potential of biotechnology in US-Poland ...
Click on the link to read the full article at Polish News (This link will open in a new window)BioMarin Pharmaceutical reports 1Q profit
30 April 2010
BioMarin Pharmaceutical Inc. on Thursday reported a first-quarter profit on a boost in sales of enzyme replacement therapies. BioMarin earned just under ...
Click on the link to read the full article at BusinessWeek (This link will open in a new window)Arnold Porter > Bracing for Increased FCPA Enforcement in the Pharmaceutical ...
30 April 2010
Source: Arnold & Porter - The Department of Justice (DOJ) announced the Foreign Corrupt Practices Act (FCPA) pharmaceutical and device industry Initiative ...
Click on the link to read the full article at Linex Legal (registration) (This link will open in a new window)Immunogen 3Q loss widens on revenue drop, costs
29 April 2010
Biotechnology company Immunogen Inc. on Thursday reported a wider fiscal third-quarter loss on a mix of lower revenue and higher operating costs. ...
Click on the link to read the full article at The Associated Press (This link will open in a new window)Pharma Reverse Patent Payments Are Not An Antitrust Violation
29 April 2010
At the conclusion of the 180 days the generic drug market would open up for all generic manufacturers, thereby allowing for generics to come to market more ...
Click on the link to read the full article at IPWatchdog.com (This link will open in a new window)New drugs fill the gap at Shire
29 April 2010
?There are only two authorised generics,? said Angel Russell, chief executive of Shire. ?Those generic companies have chosen not to drop the price very ...
Click on the link to read the full article at Financial Times (This link will open in a new window)Mylan sticks to full-year forecast, shares fall
29 April 2010
O) posted a better-than-expected first-quarter profit on Thursday, helped by strong overseas sales, but the generic drugmaker maintained its full-year ...
Click on the link to read the full article at Reuters (This link will open in a new window)Pharmaceutical Stock Alert for Somaxon Pharmaceuticals Inc. Issued by ...
29 April 2010
Somaxon Pharmaceuticals Inc. (SOMX) is a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the ...
Click on the link to read the full article at MarketWatch (press release) (This link will open in a new window)Biocon's consolidated net before exceptional items up by 22%, dividend at 70%
29 April 2010
Biocon Ltd, a Rs 2300 crore plus leading biotechnology company, has posted satisfactory growth in top line as well as bottom line during the year ended ...
Click on the link to read the full article at pharmabiz.com (This link will open in a new window)
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
